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Background
Chronic anterior uveitis is the most common ocular
complication of Juvenile Idiopathic Arthritis (JIA) pre-
dominantly affecting young girls with early onset oligo-
JIA and seropositive antinuclear antibodies (ANA).
Aim
We retrospectively evaluated the efficacy of adalimumab
in 6 children with refractory JIA related uveitis.
Methods
We analyzed 6 children (5 girls/1 boy) with JIA (5 per-
s i s t e n to l i g o - ,1e x t e n d e do l i g o -J I A )a n dc h r o n i cu v e i -
tis. All children were ANA seropositive. Uveitis was
bilateral in 5 children and appeared in half of the chil-
dren after the presentation of arthritis, in 2 children
concomitantly with arthritis and in 1 child before
arthritis.
Results
Ocular symptoms were unresponsive to treatment with
local and systemic steroids, methotrexate plus cyclos-
porine in all patients. One child had also received eta-
nercept for 2.5 years with poor response. Due to
frequent relapses of uveitis (especially when tapering
local steroids) we commenced treatment with adalimu-
mab (24mg/m
2 of body surface sc/14 days), while
cyclosporine was withdrawn. The mean duration of
uveitis until then was 27 months and the mean age of
patients at the initiation of treatment was 7.3 years. All
patients had at least one complication of uveitis (syne-
chiae: 2 children, band keratopathy: 2 children, cystoid
macular edema: 2 children, cataract: 1 child, glaucoma:
2 children). The mean duration of adalimumab treat-
ment was 4.5 months. No side effects were observed.
During adalimumab treatment uveitis subsided in all
patients with no recurrence neither requiring local
treatment. Methotrexate was reduced to the lower
dose of 7.5 mg/wk.
Conclusions
Adalimumab, a fully humanized anti-TNF antibody,
appears to be a promising, effective and safe agent in
patients with refractory JIA related uveitis.
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